Resumen de Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin�s lymphoma

Laura Galán, Antonio C. Sánchez, B. Cantos Sánchez de Ibargüen, Mariano Provencio Pulla

• Nodular lymphocyte-predominant Hodgkin�s lymphoma (NLPHL) accounts for approximately 5% of Hodgkin�s lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy.